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Abstract
Background: Depression and anxiety are very common in people with chronic obstructive pulmonary disease (COPD) and
are associated with excess morbidity and mortality. Patients prefer non-drug treatments and clinical guidelines promote
non-pharmacological interventions as first line therapy for depression and anxiety in people with long term conditions.
However the comparative effectiveness of psychological and lifestyle interventions among COPD patients is not known. We
assessed whether complex psychological and/or lifestyle interventions are effective in reducing symptoms of anxiety and
depression in patients with COPD. We then determined what types of psychological and lifestyle interventions are most
effective.
Methods and Findings: Systematic review of randomised controlled trials of psychological and/or lifestyle interventions for
adults with COPD that measured symptoms of depression and/or anxiety. CENTRAL, Medline, Embase, PsychINFO, CINAHL,
ISI Web of Science and Scopus were searched up to April 2012. Meta-analyses using random effects models were
undertaken to estimate the average effect of interventions on depression and anxiety. Thirty independent comparisons
from 29 randomised controlled trials (n = 2063) were included in the meta-analysis. Overall, psychological and/or lifestyle
interventions were associated with small reductions in symptoms of depression (standardised mean difference 20.28, 95%
confidence interval 20.41 to 20.14) and anxiety (standardised mean difference 20.23, 95% confidence interval 20.38 to
20.09). Multi-component exercise training was the only intervention subgroup associated with significant treatment effects
for depression (standardised mean difference20.47, 95% confidence interval20.66 to20.28), and for anxiety (standardised
mean difference 20.45, 95% confidence interval 20.71 to 20.18).
Conclusions: Complex psychological and/or lifestyle interventions that include an exercise component significantly improve
symptoms of depression and anxiety in people with COPD. Furthermore, multi-component exercise training effectively
reduces symptoms of anxiety and depression in all people with COPD regardless of severity of depression or anxiety,
highlighting the importance of promoting physical activity in this population.
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Introduction
One in four patients with chronic obstructive pulmonary disease
(COPD) will have clinically significant depression, which is twice
the prevalence observed in people without COPD [1]. Similarly,
compared with matched controls, people with COPD are at least
twice as likely to experience anxiety [2]. Inflammatory and
physiologic changes associated with COPD have been implicated
in the onset of depression and anxiety [3], although there is strong
evidence to suggest that subjective health status is a better
predictor of depression in COPD than biological or physiological
markers [4].
Irrespective of cause, depression and anxiety have profound
consequences for the health of patients with COPD. Depression is
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associated with increased mortality, impaired health related
quality of life and longer hospital stay after acute exacerbation
[5], increased risk of exacerbation and hospital admission [6],
hospital readmission [7], and poorer exercise performance [8].
Equally, anxiety is associated with increased risk of exacerbations,
poorer health related quality of life and worse exercise perfor-
mance [2], relapse within one-month of receiving emergency
treatment [9], and hospital readmission [10].
In the UK, the National Institute for Health and Clinical
Excellence have published guidelines for treating depression and
anxiety in people with long term conditions [11]. Treatments
include psychological therapies with or without antidepressant
medication. Importantly the National Institute for Health and
Clinical Excellence guideline for COPD emphasises offering
patients psychological and psychosocial interventions, including
behavioural approaches such as pulmonary rehabilitation, before
considering antidepressants [12].
However, the comparative effects of different psychological
interventions remains uncertain in long term conditions, and the
relevance of systematic review data is largely confined to treatment
of depression rather than both depression and anxiety, which
commonly coexist in people with long term conditions [11].
Moreover, the evidence for using psychological interventions in
COPD patients is equivocal. While there is some support for
treating depression and anxiety in COPD using cognitive and
behavioural therapy (CBT), (with or without exercise or educa-
tion), evidence is largely derived from either small randomised
controlled trials or uncontrolled and non-randomised studies
[13,14]. Whereas Rose et al found insufficient evidence to support
the use of psychologically-based treatments to reduce anxiety [15],
a more recent meta-analysis of eight psychotherapeutic and one
relaxation intervention reported a small but significant effect on
anxiety (r=20.27, 95% confidence interval 20.41 to 20.14), but
not depression [16]. Previous reviews of pulmonary rehabilitation
have indicated that 4-week programmes can improve fatigue and
emotional function, but these reviews either included trials that did
not specifically address effects on anxiety and depression [17], or
included non-randomised trials known to be affected by selection
bias [18].
Attempts to systematically review and quantify the effectiveness
of a more broad range of complex, non-pharmacological
interventions, including psycho-educational and lifestyle interven-
tions, on mental health in COPD have similarly been confounded
by methodologically heterogeneous approaches [19,20], leading to
uncertainty about which interventions to use in this population.
We have therefore conducted a systematic review and meta-
analysis of randomised controlled trials of complex psychological
and/or lifestyle interventions for managing COPD. Our first
objective was to assess whether complex interventions that
incorporate psychological and/or lifestyle components are effec-
tive in reducing symptoms of anxiety and depression in patients
with COPD. Secondly, we determined what types of complex
psychological and/or lifestyle interventions are most effective.
Methods
This systematic review is reported in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses Statement (Appendix S1) [21]. No formal protocol was
published.
Information Sources and Search Strategy
The following electronic databases were searched: Cochrane
Central Register of Controlled Trials (CENTRAL, issue 10, 2010),
Medline In-Process and Other Non-Indexed Citations (Ovid) and
Medline (Ovid) from inception to January 2011, Embase (Ovid)
from inception to January 2011, PyschINFO (Ovid) from
inception to January 2011, Cinahl (Ovid), 1981 to January
2011, ISI Web of Science 1945 to January 2011, and Scopus. In
addition we searched reference lists of included studies and of
three reviews of psychological management of COPD that were
not identified in the electronic search [22–24]. All searches were
carried out between October 2010 and January 2011 and updated
in April 2012. Non-English publications were translated. The full
search strategy for each database is available in Appendix S2.
Eligibility Criteria
Studies were eligible for inclusion in this review if they met the
following criteria:
Study design: cluster or individual randomised controlled trials.
Population: individuals with chronic obstructive pulmonary
disease confirmed by post-bronchodilator spirometry of forced
expiratory volume in 1 second/forced vial capacity ratio of ,70%
and a forced expiratory volume in 1 second of ,80%.
Intervention: single or multiple component interventions that
include psychological and/or lifestyle components to change
knowledge, attitudes, beliefs, emotions, skills and/or behaviour in
people with COPD. Studies that included patients treated for
depression and/or anxiety with psychotropic medications were
excluded. Interventions were classified based on an updated
taxonomy of behaviour change techniques [25] (Table 1).
Table 1. Classification of intervention components.
Type of
intervention Description Components
Lifestyle General education Basic provision of information,
commonly using didactic
techniques
General discussion Discussions facilitated by a
professional or lay leader
Exercise training Illness-specific exercise
Skills and self-
management training
Teaching of practical skills to
improve illness
Behaviour therapy Use of behavioural techniques,
such as goal setting, to improve
illness
Relapse prevention Discussion of how to maintain
positive change and prevent future
relapse
Psychological Problem-solving
techniques
Identification of problems/barriers
to behaviour change and
techniques to overcome them
Cognitive behavioural
therapy
Use or teaching of cognitive and
behavioural techniques to invoke
positive psychological change
Social support Use of teaching of techniques to
improve social support
Relaxation Practice of relaxation techniques,
including imagery and distraction
Biofeedback Biological feedback to support
relaxation
Miscellaneous Mental health interventions lacking
detailed description e.g. stress
management
doi:10.1371/journal.pone.0060532.t001
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Figure 1. Risk of bias summary: review authors’ judgements
about each risk of bias item for each included study.
doi:10.1371/journal.pone.0060532.g001
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Comparators: any control (e.g. waiting list, usual care, attention
or active control).
Outcomes: standardised measure of depression and/or anxiety.
We excluded studies and reports not published in peer reviewed
journals, editorials, opinions and commentaries.
Study Selection
Titles and abstracts were independently screened by four
reviewers, and full papers of potentially relevant abstracts were
retrieved. Full text versions of abstracts were independently
screened and final decisions about eligibility were made at a
consensus meeting with all review authors. Research staff with
relevant language skills translated and interpreted non-English
publications.
Data Extraction
Data were extracted and cross-checked by pairs of reviewers
using a standardised data extraction form used in a similar review
of psychological interventions in diabetes [26]. Disagreements
were resolved by discussion with two other reviewers (PC and CD).
We contacted study authors to retrieve data not available in
published study reports. Data were extracted on patient charac-
teristics including age, gender, severity of COPD (classified
according to the Global Initiative for Chronic Obstructive Lung
Disease staging) [27], depression and anxiety severity at baseline,
and whether patients were recruited on the basis of identified
depression and/or anxiety. Data extracted on interventions
included intensity (duration, number, and length of sessions),
setting (e.g. primary care, community centre), mode of delivery
Figure 2. Effects of complex interventions on self-reported depression symptoms at post-treatment. Note: Meta-analysis of Individual
trial and pooled effects. Random effects model used. 95% CI = 95% confidence intervals; SMD = standardised mean difference.
doi:10.1371/journal.pone.0060532.g002
Treating Anxiety and Depression in COPD
PLOS ONE | www.plosone.org 9 April 2013 | Volume 8 | Issue 4 | e60532
(e.g. individual or group, face to face or remote delivery), and the
professionals involved (e.g. mental health professional, respiratory
nurse). Data on outcomes relevant to the review (post treatment
depression and anxiety symptoms), comparator, and risk of bias
were also extracted. Where studies combined COPD data with
data for other respiratory disorders we wrote to authors to obtain
separate data relevant to COPD patients.
Risk of Bias
Risk of bias assessments were conducted independently for all
included studies by two reviewers (CG and JK) using the Cochrane
Collaboration tool [28]; discrepancies were resolved by discussion
with a third reviewer (PC). Specifically, assessments were made
that relate to: randomisation sequence generation, allocation bias,
blinding of outcome assessment, losses to follow-up.20% [29],
incomplete outcome data (adequate statistical handling of missing
data), and intention-to-treat. Evaluations of risk of bias associated
with blinding of outcome assessments and incomplete outcome
data were restricted to depression and anxiety outcomes.
Data Analysis and Synthesis
For each study that included continuous outcomes for
depression and anxiety, a standardised mean difference (SMD)
was calculated by taking the mean of the intervention group minus
the mean of the control group, divided by the pooled standard
deviation (SD). If there were several follow-ups we used the
outcome data closest to post-treatment. Effect sizes expressed as
SMDs are a useful method to compare the effect of an intervention
across studies when different measures (such as different depres-
sion scales) are used. In keeping with established cut-offs of effect
in behavioural medicine, effect sizes of 0.56 to 1.2 were
categorised as large; effect sizes of 0.33 to 0.55 as moderate, and
effect sizes #0.32 as small [30]. In this review, negative effect sizes
indicated that the intervention improved depression and anxiety;
statements about significance refer to statistical significance within
95% confidence intervals. Where exact means and SDs were
missing from published reports or not provided by the authors
(k = 4) we estimated effect sizes using conventional methods [31],
from exact P values [32,33], and from a figure shown in the
articles reviewed [34,35]. If an SD was missing (k= 2) [36,37] we
Figure 3. Effects of complex interventions on self-reported anxiety symptoms at post-treatment. Note: Meta-analysis of individual trial
and pooled effects. Random effects model used. 95% CI = 95% confidence intervals; SMD = standardised mean difference.
doi:10.1371/journal.pone.0060532.g003
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imputed SDs from a comparable study in the meta-analysis that
used the same measure [38]. Where trials reported two
intervention groups and a single control group, separate SMDs
were calculated for each intervention group but in the pooled
analyses the sample size of the control group was halved to avoid
double counting.
Meta-analyses using random effects models were undertaken to
estimate the average effect of interventions on symptoms of
depression and anxiety. Heterogeneity was analysed with the I2
index which represents the percentage of the total variability in a
set of effect sizes due to between-study variability, rather than
sampling error alone [39]; and by using Cochran’s Q test, which is
calculated as the weighted sum of squared differences between
individual study effects and the pooled effect across studies. The Q
statistic follows a x2 distribution with k-1 degrees of freedom,
where k is equal to the number of studies contributing to the meta-
analysis [31]; Q.k -1 suggests statistical heterogeneity with a cut-
off value of 0.10.
Figure 4. Funnel plot of effect size versus standard error for depression outcomes.
doi:10.1371/journal.pone.0060532.g004
Figure 5. Funnel plot of effect size versus standard error for anxiety outcomes.
doi:10.1371/journal.pone.0060532.g005
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The possibility of small publication bias (owing to the chance
that significant studies are selectively published and not represen-
tative of all completed studies) was examined visually by
scrutinising funnel plots and statistically using Egger’s test [40].
Meta-analysis and tests for small study bias were performed
using Stata version 12 (Stata Corp. College Station, TX).
Sensitivity and Subgroup Analysis
We carried out a pre-specified sensitivity analysis by removing
studies where allocation concealment was either inadequate or not
known from the overall pooled analysis to evaluate the effect of risk
of bias; trials in which randomisation is inadequately concealed or
inadequately reported are known to be empirically associated with
exaggerated treatment effects [41]. In addition, we also tested,
post-hoc, whether missing data impacted on the size and direction
of effect sizes by running a sensitivity analysis that excluded studies
Figure 6. Effects of complex interventions by sub-group on self-reported symptoms of depression at post-treatment. Note: Random
effects model used. 95% CI = 95% confidence interval; SMD = standardised mean difference.
doi:10.1371/journal.pone.0060532.g006
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that reported losses of .20% at follow-up or where losses to
follow-up were unknown, and studies that either did not report
using intention-to-treat, or where it was not possible to judge if
intention-to-treat had been used.
We undertook a subgroup analysis to investigate treatment
effects within four separate groups of interventions: cognitive and
behaviour therapy (CBT), multi-component exercise training, self-
management education, and relaxation. To determine whether
severity of depression and/or anxiety were associated with the
effectiveness of interventions, we investigated treatment effects in
two population subgroups: 1) studies that included confirmed
depressed and/or anxious samples or above threshold samples;
and 2) studies where depression and/or anxiety severity was
unknown at baseline.
In addition, we undertook, post-hoc, sub-group analysis to
determine the effects of all non-exercise based interventions to
enable comparison with effect sizes for the overall pooled analyses
for both depression and anxiety.
Figure 7. Effects of complex interventions by sub-group on self-reported symptoms of anxiety at post-treatment. Note: Random
effects model used. 95% CI = 95% confidence interval; SMD = standardised mean difference.
doi:10.1371/journal.pone.0060532.g007
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Results
Characteristics of Populations
Thirty two studies met the inclusion criteria, and included 35
relevant comparisons, of which 30 (n = 2063) could be included in
the meta-analysis (Figure S1). All included studies were individ-
ually randomised controlled trials. The COPD patients had a
median age of 66.3 years; one study recruited a male only sample
(median 59% male). The majority of studies recruited patients with
moderate [33–36,42–48] or severe COPD [38,49–60]; one study
recruited patients with mild to moderate COPD [37], and in three
studies patients in the intervention group had milder disease than
patients in the control group, but this did result in baseline
imbalance [32,61,62]. Only a minority of studies (k= 5) recruited
patients with identified depression and anxiety [37,44,50,51,56].
In addition, using established cut-offs, seven studies reported
baseline mean scores indicative of mild depression and four studies
reported baseline mean scores indicative of mild anxiety. The
average length of follow-up at post-treatment was 10.5 weeks
(range 4 to 52 weeks). See Table 2 for population characteristics.
Characteristics of Interventions
The content, duration, intensity and delivery of the interven-
tions varied considerably between the included trials. Over half
(65%) of the interventions included both psychological and lifestyle
components, while six included only psychological components
[35,42,44,45,55,56], and four focused on lifestyle alone
[34,38,46,48]. The most common psychological components were
cognitive and behavioural interventions, problem solving tech-
niques, relaxation and miscellaneous stress management interven-
tions. The most common lifestyle components were structured
exercise training, skills training, and education, typically as part of
a pulmonary rehabilitation programme. The average number of
treatment contacts (including remote contacts) was 18 (range 1 to
63), and the length of treatment sessions ranged from 30 to 240
minutes (mean 81.5 hours). Mean length of interventions was 11
weeks. A wide range of professionals and para-professionals (e.g.
lay trainers) delivered the interventions, with the majority
delivered face to face, either in groups or to individuals (see
Table 3 for characteristics of interventions).
Figure 8. Effects on self-reported symptoms of depression in sub-group of non-exercise based complex interventions. Note: Random
effects model used. 95% CI = 95% confidence interval; SMD = standardised mean difference.
doi:10.1371/journal.pone.0060532.g008
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Risk of Bias
Seventeen (59%) of the 29 trials described an adequate method
of random sequence generation, but only nine reported adequate
methods of allocation concealment; the method of allocation
concealment was unclear in 19 (65%) trials, and one trial did not
conceal treatment allocation (Figure 1). Blinding of outcome
assessors for anxiety and depression outcomes was reported in ten
trials (34%). Losses to follow-up of .20% occurred in nine (31%)
trials but only two of these reported using statistical methods (full
information maximum likelihood method and substitution of
baseline scores) to replace missing values at follow-up. Thirteen
(45%) trials stated that an intention-to-treat approach was used.
Meta-analysis
Are psychological and lifestyle interventions effective
in reducing symptoms of anxiety and depression in
patients with COPD? Depression was reported in 29 trials and
anxiety was reported in 26 trials. Interventions were associated
with small, significant improvements in depression (SMD 20.28,
95% confidence interval 20.41 to 20.14, I2 = 47.5%, P = 0.003;
Figure 2) and in anxiety (SMD 20.24, 95% confidence interval
20.39 to 20.09, I2 = 56.4%, P = 0.000; Figure 3).
Small Study Bias
We found no evidence of funnel plot asymmetry for either
depression (Egger test P = 0.413; Figure 4) or anxiety (Egger test
P = 0.295; Figure 5).
Sensitivity Analysis
Does risk of bias impact the size and direction of
treatment effects? We removed from the pooled analyses for
depression and anxiety studies in which the method of allocation
concealment was either not reported or was inadequate. For
depression, nine studies remained in the meta-analysis; the
magnitude of the effect size increased marginally compared with
the larger pooled analysis (SMD 20.32, 95% confidence interval
20.56 to 20.08, I2 = 59%, P = 0.01). For anxiety, eight studies
remained in the meta-analysis, resulting in a small reduction of the
effect size compared with the larger pooled analysis (SMD 20.21,
95% confidence interval 20.40 to 20.02, I2 = 33%, P = 0.16).
In a separate sensitivity analysis we also removed from the
pooled analyses for depression and anxiety studies which reported
losses of .20% at follow-up or where losses to follow-up were
unknown, and studies that either did not report using intention-to-
treat, or where it was not possible to judge if intention-to-treat had
Figure 9. Effects on self-reported symptoms of anxiety in sub-group of non-exercise based complex interventions. Note: Random
effects model used. 95% CI = 95% confidence interval; SMD = standardised mean difference.
doi:10.1371/journal.pone.0060532.g009
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been used. For depression, 17 studies remained in the meta-
analysis resulting in a small reduction in the effect size, and lower
but still significant heterogeneity compared with the larger pooled
analysis (SMD 20.26, 95% confidence interval 20.41 to 20.12,
I2 = 39.3%, P = 0.049). For anxiety, 11 studies remained in the
meta-analysis, resulting in a small reduction in the effect size and
non-significant heterogeneity compared with the larger pooled
analysis (SMD 20.20, 95% confidence interval 20.35 to 20.05,
I2 = 21.2%, P = 0.242).
Subgroup Analyses
What types of psychological and lifestyle interventions
are most effective? The direction and magnitude of effect sizes
were similar across the four intervention subgroups for both
depression and anxiety outcomes (Figure 6 and Figure 7). The
subgroup of trials that used multi-component exercise training
[32,34,43,45,48,51–54,57,59,60,62] were associated with moder-
ate and significant effects but exhibited moderate to substantial
heterogeneity (for depression I2 = 43.9%, P = 0.040; for anxiety
I2 = 63.3%, P = 0.002). Small but non-significant effects were
observed in the subgroup of trials that tested relaxation techniques
[33,42,58,61]. Similarly, the subgroup of trials that tested CBT
[35,37,44,49,55,56,63] were associated with the small, non-
significant treatment effects. The subgroup that tested self-
management education [36,46,47,50,52] were associated with no
treatment differences between intervention and control groups for
either depression or anxiety.
When studies that only tested non-exercise based complex
interventions were pooled in a sub-group the overall results for
depression (k= 17) and for anxiety (k= 11) favoured the interven-
tion, but were non-significant (Figure 8 and Figure 9).
Do these effects vary by patient population? In the
subgroup of studies (k= 13) that included confirmed depressed or
above threshold samples the effects were very similar to the pooled
effects from the larger group of treatment comparisons, (SMD
20.29, 95% confidence interval 20.49 to 20.10, I2 = 54.6%,
P = 0.007) (Figure 10). The effects of the subgroup of studies (k= 8)
that included samples of confirmed anxious and above threshold
samples were, like the pooled effects from the larger group of
comparisons, small, but significant (SMD 20.21, 95% confidence
interval 20.36 to 20.03, I2 = 4.4%, P = 0.398) (Figure 11). Small,
significant treatment effects were also observed for depression
outcomes (SMD 20.24, 95% confidence interval 20.41 to 20.08,
I2 = 39.6%, P = 0.052) and anxiety outcomes (SMD 20.27, 95%
confidence interval 20.49 to 20.05, I2 = 67.3%, P = 0.000) in the
Figure 10. Effects on self-reported symptoms of depression in trials that included confirmed depressed samples or above
threshold samples. Note: Random effects model used. 95% CI = 95% confidence intervals; SMD = standardised mean difference.
doi:10.1371/journal.pone.0060532.g010
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subgroup of studies that included samples where depression
(k= 16) and anxiety (k= 17) severity was unknown at baseline
(Figure 12 and Figure 13).
Discussion
Main Findings
This meta-analysis of 29 trials (30 comparisons) shows that
complex psychological and/or lifestyle interventions that include
exercise components are associated with moderate and significant
treatment effects over the short term compared with usual care or
active control groups. Small, non-significant treatment effects were
found for the subgroups of trials that tested CBT and relaxation
techniques. No significant difference in treatment effects were
found for trials that compared self-management education with a
control group. Overall, treatment effects were not substantially
different in the subgroup of studies that included confirmed
depressed and/or anxious samples or above threshold samples,
and the subgroup of studies that included samples where severity
of depression and/or anxiety was unknown.
Strengths and Limitations
This systematic review used rigorous search methods to identify
all randomised controlled trials of complex interventions that
included psychological and/or lifestyle components and measured
depression and/or anxiety across a broad range of severity in
people with COPD. Included trials differed significantly in terms
of interventions, patient populations, study quality and follow-up
times, which limits the extent to which broad conclusions can be
made about the overall effectiveness of complex interventions for
depression and anxiety in COPD populations.
However, we increased homogeneity by standardising follow-up
times across outcomes and estimates of heterogeneity in the pooled
analyses were moderate by conventional thresholds [39]. More-
over, there is a strong argument for avoiding narrow approaches
to meta-analysis and to instead adopt broad and inclusive
approaches that maximise power and allow exploratory (subgroup)
analyses – meta-analyses can tolerate substantial clinical and
methodological heterogeneity and publication bias and study
quality may be a more important threats to validity of results [64].
We therefore tested for publication bias and investigated whether
selection bias owing to inadequate allocation concealment
exaggerated treatment effects for both outcomes. In addition we
undertook a small series of pre-planned subgroup analyses to
determine the relative effects of different interventions. While this
approach might provide more useful data to support design and
delivery of the most effective interventions for managing
depression and anxiety in COPD, such subgroup analyses should
be interpreted cautiously because other, unanalysed differences
between studies might account for the results [65].
The optimal strategy to explore heterogeneity is to therefore use
meta-regression which investigates whether particular covariates
Figure 11. Effects on self-reported symptoms of anxiety in trials that included confirmed anxious samples or above threshold
samples. Note: Random effects model used. 95% CI = 95% confidence intervals; SMD = standardised mean difference.
doi:10.1371/journal.pone.0060532.g011
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(potential ‘effect modifiers’) explain any of the heterogeneity of
treatment effects between studies [66]. However, the results of
meta-regression only represent observational not causal associa-
tions and lack power in the presence of small sample sizes. In
addition, because the vast majority of complex intervention trials
are still not designed, conducted or reported in line with the UK
Medical Research Council Framework [67] it is difficult to isolate
the active ingredients of interventions such as those included in this
review using meta-regression, leading to calls to strengthen and
improve the reliability of specifications of characteristics of
behaviour change interventions [68].
It is plausible that the small effects of the overall pooled analyses
reflect that only a subset of trials included in this review recruited
patients with confirmed depression and/or anxiety. However,
compared with the larger pooled analyses, treatment effects were
not substantially larger in the subgroup of trials that included
samples of confirmed depressed and/or anxious patients or above
threshold samples. Furthermore, small, significant treatment
effects were associated with the subgroup of trials that included
samples where the severity of depression and/or anxiety status was
not known. These results suggest that all trials in this review will
have included patients with symptoms of depression and/or
anxiety, including sub-threshold symptoms, which are known to
affect health outcomes in long term conditions and should be
proactively managed [69].
Finally, because the meta-analysis was based on post-interven-
tion sample sizes it is possible that the results do not reflect
intention-to-treat analyses but rather available case analyses. Even
in those studies that imputed missing data using conventional
methods, the final sample sizes may not truly reflect intention-to-
treat analyses [70]. However, in the absence of raw individual
patient data the meta-analyst is therefore reliant on using data
from participants whose results are known and should instead
address the potential impact of missing data through risk of bias
assessments [65]. We followed this advice by performing a
sensitivity analysis to exclude studies where intention-to-treat was
not used or reported and where losses to follow up exceeded 20%.
While there appeared to be no clinically relevant differences in
observed effect sizes between this sensitivity analysis and the
overall pooled analysis the presence or absence of an intention-to-
treat approach and losses to follow-up.20% may well account for
significant amounts of heterogeneity, as indicated by the changes
we observed in the significance tests for heterogeneity.
Figure 12. Effects on self-reported symptoms of depression in trials where severity of depression was unknown at baseline. Note:
Random effects model used. 95% CI = 95% confidence intervals; SMD = standardised mean difference.
doi:10.1371/journal.pone.0060532.g012
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Additionally, three of the eligible studies did not contain meta-
analysable data and attempts to contact study authors failed to
recover usable data [71–73].
Implications for Research and Practice
The overall results of this review are in-keeping with those of
comparable comprehensive reviews of the effectiveness of complex
psychological and lifestyle interventions on depression in people
with diabetes [26] and coronary heart disease [74]. All three
reviews have shown that overall, complex psychological and/or
lifestyle intervention reduce depression but the effects are small.
However, our review differs from those by Harkness et al and
Dickens et al because we have shown that the small but significant
effects observed for the pooled analyses for both depression and
anxiety outcomes is largely driven by the inclusion of positive trials
that tested exercise interventions. Indeed, multi-component
exercise training with or without psychological components, and
ordinarily given as part of pulmonary rehabilitation, were the only
sub-group of interventions that significantly reduce both depres-
sion and anxiety; this remained true even when outliers were
removed from the analyses [38,59]. When expressed as a binomial
effect the estimate of effect of multi-component exercise training
on depression is equivalent to a clinical effect of 22% beyond
chance, potentially benefiting 193 of the 878 patients included in
this subgroup of trials in this review. In terms of absolute risk
reduction, this is equivalent to a number needed to treat of 5–
reductions in symptoms of depression would be expected in 1 in 5
(95% confidence interval 3.5 to 6.4) patients exposed to multi-
component exercise training.
When expressed as a binomial effect, the effect of multi-
component exercise training on anxiety is less than for depression,
equivalent to a clinical effect of 9.8% beyond chance, potentially
benefiting 73 of the 719 patients in this subgroup of trials included
in this review. This equates to a number needed to treat of 11–
reductions in symptoms of anxiety would be expected in 1 in 11
(95% confidence interval 5.8 to 38.5) patients exposed to multi-
component exercise training.
Exercise may offer patients an alternative and effective
approach to managing depression, especially for those with
physical comorbidities who have concerns about the antagonistic
effects and burden of multiple medications [75]. However the
science underpinning the use of exercise to treat depression is
Figure 13. Effects on self-reported symptoms of anxiety in trials where severity of anxiety was unknown at baseline. Note: Random
effects model used. 95% CI = 95% confidence intervals; SMD = standardised mean difference.
doi:10.1371/journal.pone.0060532.g013
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uncertain and even less robust in relation to anxiety. Based on high
quality trials alone a Cochrane review has shown that exercise can
improve depression in adults without long term conditions, and is
as effective as cognitive therapy, but the effects are small [76]. By
comparison two large meta-analyses concluded that exercise
training, undertaken for 30 minutes for 3 to 12 weeks has positive
effects on depression and anxiety in people with long term
conditions [77,78]. While novel in their insights about the efficacy
of exercise for depression and anxiety in chronically ill populations
the reviews by Herring et al only included a small number of
COPD trials and did not look at the comparative effectiveness of
other psychological or lifestyle interventions. By contrast our
review is the first to specifically demonstrate that structured
exercise training significantly reduces both symptoms of depression
and anxiety in people with COPD. Furthermore we have showed
that structured exercise training is more effective than other,
complex psychological behavioural and lifestyle interventions
previously thought to improve mental health in people with
COPD.
While this review therefore represents a considerable advance
on understanding the positive role exercise training can play in
managing depression and anxiety in COPD, its main finding
appears at odds with the results of a facilitated exercise
intervention which increased physical activity but did not reduce
depression or use of anti-depressants over 12 months in primary
care patients with recognised depression [79]. However, the
negative and controversial results of the trial by Chalder et al can
be partly be explained by the fact that patients in the two arms
engaged in very similar levels of exercise. Additionally, it is likely
that the overall effect size of this trial was diluted by heterogeneity
of response among individuals and we do not fully understand the
factors that relate to this heterogeneity [80]. Moreover, outside of
the context of pulmonary rehabilitation, increasing physical
activity in sedentary and depressed and/or anxious COPD
patients remains a challenge. This is especially true in primary
care, but advice and counselling are effective methods to promote
increased physical activity for people with and without long term
conditions [81], whereas the cost-benefits of exercise referral
schemes are uncertain [82].
The finding that CBT is not as effective as exercise training for
depression or anxiety in COPD is inconsistent with clinical
guidelines that recommend using low intensity psychological
interventions as first line therapy for treating depression and
anxiety in people with long term conditions [11]. CBT has a
similar efficacy profile to antidepressants for managing depression
and anxiety disorders [83], but in this review we found that the
effectiveness of CBT is possibly reduced in the presence of COPD.
Methodological parameters might partly account for this finding
as a number of included trials in this subgroup compared CBT
with active controls [55,56,63]. Alternatively, compared with
exercise, CBT places relatively high cognitive demands on patients
and treatment response to this form of psychological therapy may
be compromised among older adults with cognitive impairments
in memory, attention, and executive function. Patients in the CBT
trials included in this review were generally over 60 years old and
their engagement with CBT could have thus been affected by the
presence of cognitive impairments. In addition, there is consistent
evidence that COPD, in both non-hypoxic and hypoxic individ-
uals, is associated with cognitive dysfunction not ordinarily
associated with other comorbidities [84], further suggesting that
CBT may not be appropriate for COPD patients with significant
cognitive impairments.
The negative results for the CBT sub-group in this review may
also owe to the fact that CBT, which centres on challenging
thoughts and setting behavioural goals, is difficult to accommodate
by people with COPD whose ruminative thinking and avoidance
behaviours are associated with real and meaningful symptoms,
especially dyspnoea. While there is growing evidence that CBT
can improve generalised anxiety disorder and global mental health
in older adults with medical diagnoses [85], psychological
interventions that promote an ‘accepting mode of response’ such
as mindfulness might be more appropriate and effective for
managing psychological distress in COPD patients, especially
breathing related anxiety. Mindfulness based interventions are
associated with longer term benefits on psychological health than
stand alone relaxation interventions [86], but their usefulness in
COPD is yet to be established [87].
The least effective interventions in this review were self-
management education programmes with or without action plans,
and case management. Self-management education in COPD can
prevent hospital admissions but they have little effect on other
important outcomes such as exacerbations, respiratory symptoms,
medication use and exercise capacity [88], and their effect on
anxiety and depression has not been specifically assessed. By
contrast, case management approaches that draw on integrated
and collaborative approaches such as the chronic care model have
been shown to reduce depression and improve physical health in
people with diabetes and coronary heart disease [89], but their
effectiveness and safety in COPD is unknown [90]. Developing
integrated and collaborative care models that enhance opportu-
nities for therapeutic synergies between mental and physical health
is a major priority of advanced health systems confronted with
increased prevalence and burden of multimorbidity [91]. There is
then scope to explore the effectiveness of collaborative care models
in the management of COPD, specifically testing whether the
integration of exercise training in such models can confer physical
and mental health benefits in people with COPD.
Conclusion
Complex psychological and/or lifestyle interventions that include
exercise training reduce symptoms of depression and anxiety in
people with COPD over the short term. Additionally, complex
interventions that included exercise training, with or without
psychological components, were associated with the largest
treatment effects in people with COPD across a range of disease
severity when compared with usual care or active control groups.
We were not able to determine the optimal dose of exercise training
but the most effective interventions in this subgroup typically
comprised 3 to 12 weeks of $30 minute sessions of group based
exercise training in the context of pulmonary rehabilitation. No
other intervention subgroups, including CBT, were associated with
significant treatment effects. Treatment effects were no larger in
trials that included confirmed depressed and/or anxious samples or
above threshold samples, than in trials where severity of depression
and anxiety was unknown at baseline. In conclusion, exercise
training can have adventitiously positive effects on psychological
health in all COPD patients, even among those with sub-threshold
levels of depression and anxiety.
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